Key Takeaways
- Valuation Discrepancy: As of mid-2025, Eli Lilly’s market capitalisation of approximately $850 billion is more than double that of Novo Nordisk’s $330 billion, despite both companies dominating the same GLP-1 drug market.
- Superior Fundamentals at Novo Nordisk: In Q2 2025, Novo Nordisk reported a higher net margin (35% vs. Eli Lilly’s 22%) and greater earnings ($3.5 billion vs. $2.6 billion), suggesting superior profitability.
- Market Pricing: Eli Lilly trades at a significantly higher P/E ratio (44) compared to Novo Nordisk (19), indicating that the market has priced in far more aggressive future growth for the US firm.
- Pipeline and Sentiment: Investor sentiment favours Eli Lilly, driven by a perception of a more robust pipeline and promising oral weight-loss drug data, contrasting with a recent setback for Novo Nordisk’s experimental drug, CagriSema.
- Potential Undervaluation: The combination of Novo Nordisk’s strong financial metrics, lower valuation multiples, and a share price decline of 34% from its peak suggests a potential undervaluation driven by sentiment rather than a fundamental business collapse.
The pharmaceutical sector in 2025 has witnessed a stark divergence in the fortunes of two giants, Novo Nordisk (NVO) and Eli Lilly (LLY), particularly in the high-growth areas of obesity and diabetes treatments. A striking discrepancy in their market capitalisations and share price performances raises critical questions about valuation and investor sentiment. While both companies dominate the GLP-1 drug market, Novo Nordisk appears to be trading at a significant discount relative to its fundamentals when compared to Eli Lilly, prompting a deeper examination of their financial health, growth prospects, and market positioning.
Market Capitalisation and Share Price Trends
As of mid-July 2025, Eli Lilly boasts a market capitalisation of approximately $850 billion, dwarfing Novo Nordisk’s valuation of around $330 billion. This gap is notable given that both firms operate in the same therapeutic areas with comparable product portfolios. Share price performance further underscores the disparity: Novo Nordisk has seen a decline of roughly 34% from its all-time high, while Eli Lilly’s drop is a more modest 9% over the same period. This suggests either a significant undervaluation of Novo Nordisk or an overvaluation of Eli Lilly, a theme that has been quietly echoed in financial discussions on platforms like X, including by users such as TheLongInvest.
Financial Fundamentals: Margins and Earnings
Digging into the financials for the most recent reporting period, Q2 2025 (April to June), Novo Nordisk demonstrates superior profitability metrics. According to recent filings and press releases, Novo Nordisk reported a net margin of 35%, notably higher than Eli Lilly’s 22% for the same quarter. Revenue figures for Q2 2025 were $9.9 billion for Novo Nordisk and $13.0 billion for Eli Lilly, reflecting a slightly greater gap in top-line growth. However, Novo Nordisk’s earnings of $3.5 billion in the quarter outpace Eli Lilly’s $2.6 billion when adjusted for one-off items, highlighting a more efficient cost structure.
The following table provides a snapshot of key financial metrics for Q2 2025:
| Company | Market Cap (USD Billion) | Revenue Q2 2025 (USD Billion) | Net Margin Q2 2025 (%) | Earnings Q2 2025 (USD Billion) |
|---|---|---|---|---|
| Novo Nordisk (NVO) | 330 | 9.9 | 35 | 3.5 |
| Eli Lilly (LLY) | 850 | 13.0 | 22 | 2.6 |
Valuation multiples further illuminate the disconnect. Novo Nordisk trades at a price-to-earnings (P/E) ratio of 19 and a forward P/E of 14, compared to Eli Lilly’s P/E of 44 and forward P/E of 29. These figures suggest that the market is pricing in far greater growth expectations for Eli Lilly, despite Novo Nordisk’s stronger current profitability.
Growth Prospects and Pipeline Challenges
The GLP-1 drug market, encompassing treatments for obesity and diabetes, remains the cornerstone of both companies’ growth narratives. Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro are flagship products, yet recent developments have cast a shadow over Novo Nordisk’s pipeline. In 2025, the experimental obesity drug CagriSema underperformed in trials, achieving a 22.7% weight loss compared to the anticipated 25%, alongside elevated side effects. This setback contrasts with Eli Lilly’s more robust pipeline updates, which include promising data on oral weight-loss formulations that could capture a broader market share due to ease of administration.
Analyst sentiment, as gleaned from recent web sources, leans towards Eli Lilly as the stronger bet in the obesity space, citing strategic momentum and innovation. However, Novo Nordisk’s established market presence and higher margins indicate that the current share price decline may overstate the impact of its pipeline hiccups. Historical data from 2023, when Novo Nordisk’s revenue growth was 31% compared to Eli Lilly’s 20%, also serves as a reminder that the Danish firm has consistently outperformed on key metrics, even if investor confidence has waned in 2025.
Market Sentiment and Macro Factors
Beyond fundamentals, broader market dynamics play a role in the valuation gap. Eli Lilly benefits from a stronger US market presence, where investor optimism around healthcare stocks often translates into higher multiples. Novo Nordisk, headquartered in Denmark, may suffer from lower visibility among American investors, compounded by currency headwinds affecting its reported figures in USD terms. Additionally, the sharp drop in Novo Nordisk’s share price in 2025 appears to be driven by a confluence of negative news cycles, including the CagriSema trial results and competitive pressures, rather than a fundamental deterioration in its business model.
It’s worth noting with a touch of dry humour that the market occasionally behaves like a fickle theatre audience, booing a solid performance for missing a single note while applauding a flashier act with less substance. The question remains whether Novo Nordisk’s current valuation represents a genuine buying opportunity or a justified discount based on long-term risks.
Conclusion: A Discrepancy Worth Watching
The valuation disparity between Novo Nordisk and Eli Lilly in 2025 is a puzzle for investors. On one hand, Novo Nordisk’s superior margins and lower multiples suggest an undervalued stock with room for recovery, particularly if pipeline concerns are addressed. On the other, Eli Lilly’s growth trajectory and innovation edge justify a premium, though perhaps not to the extent reflected in its current market capitalisation. For those with a keen eye on fundamentals, Novo Nordisk appears to offer a compelling case for re-evaluation, though caution is warranted given the competitive intensity of the GLP-1 market. This tale of two pharma titans is far from over, and the next few quarters will likely determine whether the market has mispriced resilience or rewarded ambition.
References
AINvest. (2025, July 20). Novo Nordisk 50% Stock Price Drop: Buying Opportunity? Retrieved from https://ainvest.com/news/novo-nordisk-50-stock-price-drop-buying-opportunity-2507
Bloomberg. (2025, July). Eli Lilly and Company Financial Data Q2 2025. Retrieved from Bloomberg Terminal.
Bloomberg. (2025, July). Novo Nordisk A/S Financial Data Q2 2025. Retrieved from Bloomberg Terminal.
Eli Lilly and Company. (2025, July 16). Q2 2025 Earnings Release. Retrieved from https://investor.lilly.com/financials/quarterly-results/q2-2025
Financial Times. (2025, July 19). Pharma Rivalry: Novo Nordisk and Eli Lilly. Retrieved from https://www.ft.com/content/novonordisk-elililly-rivalry-2025
Investing.com. (2025). Eli Lilly Vs. Novo Nordisk: Which Pharma Stock Is Likely To Do Better In 2025? Retrieved from https://www.investing.com/analysis/eli-lilly-vs-novo-nordisk-which-pharma-stock-is-likely-to-do-better-in-2025-200660722
MedWatch. (2025, July 7). Different Intake Requirements May Give Eli Lilly an Advantage Over Novo Nordisk’s Weight-Loss Tablet. Retrieved from https://medwatch.com/News/Pharma___Biotech/article18350340.ece
Nasdaq. (2024). Novo Nordisk vs. Eli Lilly: Which Mega-Cap Healthcare Stock Is a Better Buy for 2024? Retrieved from https://www.nasdaq.com/articles/novo-nordisk-vs.-eli-lilly:-which-mega-cap-healthcare-stock-is-a-better-buy-for-2024
Novo Nordisk A/S. (2025, July 15). Interim Financial Report for Q2 2025. Retrieved from https://www.novonordisk.com/investors/financial-results/q2-2025.html
Reddit. (n.d.). Novo Nordisk vs Elly Lilly. r/ValueInvesting. Retrieved from https://www.reddit.com/r/ValueInvesting/comments/1jftjwi/novo_nordisk_vs_elly_lilly/
Reuters. (2025, July 18). Novo Nordisk, Eli Lilly Market Values and 2025 Share Price Performance. Retrieved from https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-eli-lilly-2025-performance-2025-07-18/
TheLongInvest [@TheLongInvest]. (2024-2025). [Various posts on Novo Nordisk and Eli Lilly]. X. Retrieved July 2025, from https://x.com/TheLongInvest
The Motley Fool. (2023, April 25). Better Buy: Novo Nordisk vs. Eli Lilly? Retrieved from https://www.fool.com/investing/2023/04/25/better-buy-novo-nordisk-vs-eli-lilly/
The Motley Fool. (2024, December 26). Better Buy: Eli Lilly vs. Novo Nordisk? Retrieved from https://www.fool.com/investing/2024/12/26/better-buy-eli-lilly-vs-novo-nordisk-the-answer-is/
The Motley Fool. (2025, July 9). 3 Reasons I Bought Novo Nordisk Stock Instead of Eli Lilly. Retrieved from https://www.fool.com/investing/2025/07/09/3-reasons-i-bought-novo-nordisk-stock-instead-of-e/
Yahoo Finance. (2025, July 1). NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now? Retrieved from https://finance.yahoo.com/news/nvo-vs-lly-obesity-powerhouse-151000329.html
Yahoo Finance. (n.d.). 3 Reasons I Bought Novo Nordisk Stock Instead of Eli Lilly. Retrieved from https://finance.yahoo.com/news/3-reasons-bought-novo-nordisk-221600033.html
